| __timestamp | Amphastar Pharmaceuticals, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 18516000 |
| Thursday, January 1, 2015 | 174172000 | 34140000 |
| Friday, January 1, 2016 | 150976000 | 51872000 |
| Sunday, January 1, 2017 | 149380000 | 71772000 |
| Monday, January 1, 2018 | 187681000 | 97501000 |
| Tuesday, January 1, 2019 | 190434000 | 118590000 |
| Wednesday, January 1, 2020 | 206506000 | 169802000 |
| Friday, January 1, 2021 | 238029000 | 7491000 |
| Saturday, January 1, 2022 | 250127000 | 8799000 |
| Sunday, January 1, 2023 | 293274000 | 253598000 |
Cracking the code
In the competitive landscape of pharmaceuticals, cost efficiency is a critical metric. Over the past decade, Amphastar Pharmaceuticals, Inc. and Xencor, Inc. have showcased contrasting trajectories in their cost of revenue. From 2014 to 2023, Amphastar's cost of revenue surged by approximately 84%, peaking in 2023. This growth reflects their expanding operations and market reach. In contrast, Xencor's cost of revenue exhibited a more volatile pattern, with a significant spike in 2023, reaching nearly 253% of its 2014 value. This fluctuation could indicate strategic shifts or varying operational scales. Notably, Amphastar maintained a more consistent upward trend, suggesting a stable growth strategy. As the pharmaceutical industry continues to evolve, these insights into cost efficiency provide a window into the operational strategies of these two key players.
Cost Insights: Breaking Down Eli Lilly and Company and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: Biogen Inc. vs Xencor, Inc.
Analyzing Cost of Revenue: Insmed Incorporated and Xencor, Inc.
Cost of Revenue: Key Insights for BioMarin Pharmaceutical Inc. and Xencor, Inc.
Cost Insights: Breaking Down Grifols, S.A. and Amphastar Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Vericel Corporation vs Amphastar Pharmaceuticals, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Analyzing Cost of Revenue: Iovance Biotherapeutics, Inc. and Xencor, Inc.
Cost of Revenue Comparison: Taro Pharmaceutical Industries Ltd. vs Xencor, Inc.
Cost Insights: Breaking Down Travere Therapeutics, Inc. and Xencor, Inc.'s Expenses
Cost Insights: Breaking Down Evotec SE and Xencor, Inc.'s Expenses